New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
06:39 EDTICPTIntercept trial deaths unlikely associated with treatment, says Wedbush
Wedush believes the two deaths that occurred during the FLINT Phase 2b trial disclosed late Friday by Intercept are unlikely related to the OCA treatment. The firm says any continued weakness in shares of Intercept would be a buying opportunity and keeps an Outperform rating on the name with a $493 price target.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
06:26 EDTICPTIntercept price target lowered to $475 from $693 at Citigroup
Citigroup lowered its price target for Intercept shares to $475 on expectations investor concerns around the company's liver fibrosis drug, OCA, will persist. Citi, however, says it remains a buyer of the stock. It believes the level of concern around OCA’s cholesterol effect is overdone. The firm keeps a Buy rating on shares of Intercept.
December 18, 2014
06:33 EDTICPTIntercept coverage resumed with a Buy at Sterne Agee
Subscribe for More Information
December 15, 2014
08:58 EDTICPTIntercept reinstated with a Buy at BofA/Merrill
Subscribe for More Information
December 11, 2014
08:57 EDTICPTLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use